CA3064479A1 - Compositions and methods for treating alzheimer's disease - Google Patents

Compositions and methods for treating alzheimer's disease Download PDF

Info

Publication number
CA3064479A1
CA3064479A1 CA3064479A CA3064479A CA3064479A1 CA 3064479 A1 CA3064479 A1 CA 3064479A1 CA 3064479 A CA3064479 A CA 3064479A CA 3064479 A CA3064479 A CA 3064479A CA 3064479 A1 CA3064479 A1 CA 3064479A1
Authority
CA
Canada
Prior art keywords
therapeutic
ptpg
app
therapeutic agent
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064479A
Other languages
English (en)
French (fr)
Inventor
Yingjie Shen
Yuanzheng GU
Jerry Silver
Bradley T. Lang
Original Assignee
Case Western Reserve University
Ohio State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University, Ohio State University filed Critical Case Western Reserve University
Publication of CA3064479A1 publication Critical patent/CA3064479A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3064479A 2017-06-05 2018-06-05 Compositions and methods for treating alzheimer's disease Pending CA3064479A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515272P 2017-06-05 2017-06-05
US62/515,272 2017-06-05
PCT/US2018/036116 WO2018226735A1 (en) 2017-06-05 2018-06-05 Compositions and methods for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
CA3064479A1 true CA3064479A1 (en) 2018-12-13

Family

ID=64567326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064479A Pending CA3064479A1 (en) 2017-06-05 2018-06-05 Compositions and methods for treating alzheimer's disease

Country Status (8)

Country Link
US (1) US20200093890A1 (https=)
EP (1) EP3634979A4 (https=)
JP (1) JP2020524132A (https=)
KR (1) KR20200045446A (https=)
CN (1) CN110945011A (https=)
AU (1) AU2018281330A1 (https=)
CA (1) CA3064479A1 (https=)
WO (1) WO2018226735A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120957751A (zh) * 2023-04-03 2025-11-14 神经再生制药公司 用于神经系统修复的蛋白酪氨酸磷酸酶楔形结构域肽二聚体
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083182A2 (en) * 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010146058A1 (en) * 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
WO2012019086A2 (en) * 2010-08-06 2012-02-09 The University Of North Carolina At Chapel Hill Inhibition of lar phosphatase to enhance therapeutic angiogenesis
AU2013235422B2 (en) * 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
US9937242B2 (en) * 2012-04-09 2018-04-10 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
JP6396438B2 (ja) * 2013-06-04 2018-09-26 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
EP3454885A4 (en) * 2016-05-12 2019-12-25 Ohio State Innovation Foundation PEPTIDES AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS

Also Published As

Publication number Publication date
EP3634979A1 (en) 2020-04-15
EP3634979A4 (en) 2021-04-14
JP2020524132A (ja) 2020-08-13
KR20200045446A (ko) 2020-05-04
WO2018226735A1 (en) 2018-12-13
US20200093890A1 (en) 2020-03-26
CN110945011A (zh) 2020-03-31
AU2018281330A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
Fol et al. Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model
US7276643B2 (en) Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
EP3440094A1 (en) Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
US20220104468A1 (en) Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
AU2024266863A1 (en) Compositions and methods for treating myelin disorders
US20200093890A1 (en) Compositions and methods for treating alzheimer's disease
CA2987365A1 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
US10898550B2 (en) Compositions and methods of treating root avulsion injury
ES3023183T3 (en) Compositions and methods for treating neurological and other disorders
KR20230124010A (ko) 응집 억제를 위한 Aβ 변이체의 전달
JP2003518922A (ja) 神経変性症候群の研究のための非ヒトトランスジェニック動物
US12521371B2 (en) Modulators of alpha-synuclein
US20140314790A1 (en) Caspase 9 inhibition and bri2 peptides for treating dementia
KR20250040552A (ko) 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술
KR20260028192A (ko) 신경퇴행성 질환 및 장애의 치료 및 예방용 조성물 및 방법
WO2024050560A1 (en) Compositions and methods for treating neurodegeneration
CA3251609A1 (en) C-TERMINAL FRAGMENT OF APOLIPOPROTEIN E AND ITS APPLICATION IN THE INHIBITION OF γ-GAMMA-SECRETASE ACTIVITY
Sharma Efficacy of a novel neuronal death inhibitor in Alzheimer’s disease models

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230605

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241007